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Available online 25 August 2016Background: It has been suggested that bladder cancer can be divided into twomolecular subtypes referred to as
luminal and basal with distinct clinical behaviors and sensitivities to chemotherapy. We aimed to validate these
subtypes in several clinical cohorts and identify signature immunohistochemicalmarkers thatwould permit sim-
ple and cost-effective classiﬁcation of the disease in primary care centers.
Methods:Weanalyzed genomic expression proﬁles of bladder cancer in three cohorts of fresh frozen tumor sam-
ples: MD Anderson (n= 132), Lund (n= 308), and The Cancer Genome Atlas (TCGA) (n= 408) to validate the
expression signatures of luminal and basal subtypes and relate them to clinical follow-up data. We also used an
MDAnderson cohort of archival bladder tumor samples (n= 89) and a parallel tissue microarray to identify im-
munohistochemical markers that permitted the molecular classiﬁcation of bladder cancer.
Findings: Bladder cancers could be assigned to two candidate intrinsic molecular subtypes referred to here as lu-
minal and basal in all of the datasets analyzed. Luminal tumors were characterized by the expression signature
similar to the intermediate/superﬁcial layers of normal urothelium. They showed the upregulation of PPARγ tar-
get genes and the enrichment for FGFR3, ELF3, CDKN1A, and TSC1 mutations. In addition, luminal tumors were
characterized by the overexpression of E-Cadherin,HER2/3, Rab-25, and Src. Basal tumors showed the expression
signature similar to the basal layer of normal urothelium. They showed the upregulation of p63 target genes, the
enrichment for TP53 and RB1 mutations, and overexpression of CD49, Cyclin B1, and EGFR. Survival analyses
showed that the muscle-invasive basal bladder cancers were more aggressive when compared to luminal can-
cers. The immunohistochemical expressions of only twomarkers, luminal (GATA3) and basal (KRT5/6), were suf-
ﬁcient to identify the molecular subtypes of bladder cancer with over 90% accuracy.
Interpretation: The molecular subtypes of bladder cancer have distinct clinical behaviors and sensitivities to che-
motherapy, and a simple two-marker immunohistochemical classiﬁer can be used for prognostic and therapeutic
stratiﬁcation.
Funding: U.S. National Cancer Institute and National Institute of Health.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Bladder cancer
Biomarker1. Introduction
Recent genomic investigations of bladder cancer have revealed com-
plex alterations with heavy mutational load and frequent involvementMD Anderson Cancer Center
uston, TX, United States.
k).
. This is an open access article underof chromatin remodeling genes (Cancer Genome Atlas Research N,
2014; Gui et al., 2011; Lawrence et al., 2013). Other studies have identi-
ﬁed distinct genomic signatures associated with cancer progression, me-
tastasis and response to therapeutic manipulations (Takata et al., 2005;
Puzio-Kuter et al., 2009; Cheng et al., 2013; Van Allen et al., 2014;
Groenendijk et al., 2016; Dyrskjot et al., 2003). Several groups used
whole genome expression proﬁling to classify bladder cancer into various
distinct subtypes (Cancer Genome Atlas Research N, 2014; Damrauer et
al., 2014; Choi et al., 2014a; Lindgren et al., 2010; Sjodahl et al., 2012).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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different, they showed striking similarities to the intrinsic basal and lumi-
nal subtypes identiﬁed in human breast cancers (Damrauer et al., 2014;
Choi et al., 2014b; Perou et al., 2000). In general, the markers that are
used to classify bladder cancers into the two major groups reﬂect an ex-
pression signature of normal basal and intermediate/luminal urothelial
cell layers (Choi et al., 2014b). Most importantly, the two intrinsic sub-
types of bladder cancer show distinct clinical behaviors and responses
to frontline chemotherapy (Choi et al., 2014a; Choi et al., 2014b;
McConkey et al., 2015). In the chemotherapynaive setting, themuscle-in-
vasive bladder cancers of the basal subtype were more aggressive with
shorter survival when compared to luminal cancers (Choi et al., 2014a;
Choi et al., 2014b). On the other hand, basal bladder cancers were more
sensitive to cisplatinum based chemotherapy and the patients with this
formof the disease appeared to gainmore beneﬁts from frontline chemo-
therapy when compared to luminal subtypes (Choi et al., 2014a; Choi et
al., 2014b).
Since the classiﬁcation of bladder cancer into intrinsic molecular
subtypes provides prognostic information and may help to identify a
subgroup of patients with increased sensitivity to chemotherapy, we
performed ameta-analysis of the luminal and basal subtypes of bladder
cancer in several MD Anderson and publicly available cohorts. We also
validated the signature proﬁles of luminal and basal cancers on retro-
spectively collected parafﬁn-embedded tumor samples, as these are
the types of tissue on which the standard of clinical care is based. Final-
ly, in order to identify a minimal set of clinically applicable biomarkers
permitting simple classiﬁcation of bladder cancers into luminal and
basal subtypes, we performed image assisted analysis of selected im-
munohistochemical markers on parallel tissue microarrays.Table 1
Summary of clinical data: the MD Anderson, TCGA#, Lund,⁎ and FFPE MD Anderson cohorts.
Stage Subtype Gender F/M Tot
MD Anderson cohort
Superﬁcial(Ta-Tis) Luminal 8/26 34
Invasive Luminal 11/49 60
(T1 and higher) Basal 12/22 34
Invasive Luminal-non p53 9/36 45
(T1 and higher) Luminal-p53 2/13 15
Basal-non p53 8/8 16
Basal-p53 4/14 18
Double negative 1/3 4
TCGA cohort
Invasive Luminal 48/164 212
(T2 and higher) Basal 56/123 179
Invasive Luminal-non p53 27/106 133
(T2 and higher) Luminal-p53 21/58 79
Basal-non p53 29/69 98
Basal-p53 27/54 81
Double negative 3/14 17
Lund cohort
Superﬁcial Luminal 36/80 116
(Ta-pTis)
Invasive Luminal 27/112 139
(T1 and higher) Basal 15/23 38
Invasive Luminal-non p53 18/73 91
(T1 and higher) Luminal-p53 9/39 48
Basal-non p53 13/14 27
Basal-p53 2/9 11
Double negative 2/11 13
MD Anderson parafﬁn-embedded formalin-ﬁxed tissue cohort
Invasive Luminal 8/38 46
T2 and higher) Basal 11/18 29
Invasive Luminal-non p53 3/15 18
(T2 and higher) Lum-p53 5/23 28
Basal-non p53 6/12 18
Basal-p53 5/6 11
Double Neg 3/11 14
F, female; M, male; yr, year; SD, standard deviation; Med., median; sur., survival; mo, months;2. Methods
2.1. Patients and Study Design
The expression proﬁling studies of molecular subtypes of blad-
der cancer were conducted on four cohorts: (Cancer Genome
Atlas Research N, 2014) the MD Anderson cohort of fresh frozen
bladder tumor tissue (n = 132); (Gui et al., 2011) the cohort of
fresh frozen bladder tumor tissue from Lund University in Sweden
(n = 308) referred to as the Lund cohort; (Lawrence et al., 2013)
the Cancer Genome Atlas (TCGA) cohort of fresh frozen bladder
tumor tissue (n = 408); and (Takata et al., 2005) the MD Anderson
cohort of formalin-ﬁxed parafﬁn-embedded bladder tumor tissue
samples (n = 89) (Table 1).
TheMDAnderson cohort of fresh frozen bladder tumor samples was
from 100men and 32women (mean age 67.2 years ± 12.3 SD). The tu-
mors were classiﬁed according to theWorld Health Organization histo-
logic grading system into low-grade (n=25) and high-grade (n=107)
(Moch et al., 2016). According to the TNM staging system the tumors
were divided into superﬁcial (stage Ta-Tis; n = 34) and invasive
(stage T1and higher; n = 98) categories (Sobin et al., 2009).
The Lund cohort mRNA expression and clinical data were retrieved
from GEO (GSE32894) as per the original publication (Sjodahl et al.,
2012). This cohort consisted of fresh frozen bladder tumor tissue sam-
ples from 80 women and 228 men (mean age 70.6 years ± 11.8 SD).
The tumors were divided into non-invasive (Ta and Tis; n = 116) and
invasive (T1 and higher; n=190) according to the TNMstaging system.
The tumorswere considered low-grade (n=151) if theywere original-
ly reported as grade 1–2 and high-grade (n = 155) if they wereal Age, yr, mean ± SD Med. sur. mo 95% CI, mo
65.3 ± 11.3 NA 110.7 - NA
68.3 ± 10.6 87.9 45.1 - NA
67.9 ± 16.1 11 7.2 - NA
66.7 ± 11.3 91.4 41.6 - NA
73.1 ± 6.2 80.8 26.3 - NA
73.1 ± 8.8 10.6 6.5 - NA
63.2 ± 19.7 13.7 6.2 - NA
62.7 ± 8.1 NA 14.5 - NA
68.3 ± 11.0 46.8 31.2 - 97.1
68.0 ± 10.1 27.1 20.7 - 51.2
66.2 ± 11.3 NA 56.5 - NA
71.9 ± 9.5 28.2 22.4 - 46.8
67.6 ± 11.0 29.7 20.2 - NA
68.5 ± 9.0 24.1 16.8 - 104.6
65.6 ± 10.2 18.6 7.3 - NA
69.7 ± 12.8 NA NA - NA
70.3 ± 11.3 NA NA - NA
75.6 ± 11.1 NA 24.2 - NA
69.1 ± 11.6 NA NA - NA
72.6 ± 10.3 NA NA - NA
76.3 ± 12.1 34.8 13.4 - NA
73.7 ± 8.3 NA 24.2 - NA
66.8 ± 7.3 NA NA - NA
70.2 ± 11.6 57.3 23.4 - NA
69.2 ± 11.0 22.7 15.4 - NA
72.6 ± 13.7 20.4 17 - NA
68.7 ± 10.1 NA 36 - NA
68.9 ± 11.7 37.9 12.1 - NA
69.7 ± 10.3 19.1 15.4 - NA
68.0 ± 8.4 41.8 24.9 - NA
CI, Conﬁdence Interval. #Stage is unknown in three cases. *Stage is unknown in two cases.
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two cases the tumor staging and in another two cases grading informa-
tion were not available.
The TCGA cohort was comprised of 408 bladder tumors, most of
which were muscle-invasive tumors (stage T2 and higher; n = 405).
The level of invasion was unknown for three cases. The vast majority
of tumors were of high histologic grade (n = 384) and only a few tu-
mors were of low histologic grade (n = 21). The histologic grade was
unknown for three cases. The publicly available whole transcriptome
data (RNA-seq) andmutations of tumor sampleswith annotated clinical
and survival data were downloaded from the TCGA website (https://
tcga-data.nci.nih.gov/tcga/). In addition, the reverse phase protein
array (RPPA) data available for 126 samples comprising the expression
levels for 190 proteins were downloaded from the same website.
To assemble the MD Anderson formalin-ﬁxed parafﬁn-embedded
tissue sample cohort we searched the pathology ﬁles and randomly
selected 89 tumor samples (67 men and 22 women; mean age
69.6 years ± 0.9 SD) from cystectomy specimens with invasive bladder
cancer. The clinical information, demographic data and follow-up out-
comes were obtained from the patient's medical records. Similar to
theMD Anderson cohort of fresh frozen bladder tumor samples, the tu-
mors were graded according to World Health Organization histologic
grading system and staged according to the TNM staging system
(Moch et al., 2016; Sobin et al., 2009). All tumors in this cohort were
high-grade and muscle-invasive (stage T2 and higher). The histologic
slides were reviewed by two independent pathologists and well-pre-
served areas rich in tumor cells were identiﬁed. The corresponding
areas were marked on parafﬁn blocks and two parallel tissue cores
were obtained with a 2 mm biopsy punch (Miltex, York, PA). One core
was submitted for RNAextraction and the other corewas used for tissue
microarray preparation. The use of human samples and related clinical
data for this study was approved by the institutional IRB.2.2. Procedures
2.2.1. Microarray Experiments
RNAs from fresh frozen tissue were extracted using the mirvana
™miRNA isolation kit (Ambion, Inc.) and the microarray experiments
were performed by direct hybridization on the Illumina HumanHT-12
v3 Expression BeadChip platform as previously described (Choi et al.,
2014a). In brief, intact RNAs from samples were converted to double-
stranded cDNA, followed by in vitro transcription to generate biotin-la-
beled cRNA using Ambion Illumina TotalPrep RNA Ampliﬁcation Kit
(Illumina). The labeled cRNAwas hybridized containing complimentary
gene-speciﬁc sequences. Afterwashing the BeadChips, Cy3-Streptavidin
was added to bind to analytical probes hybridized on the BeadChips. The
chips were then scanned on Illumina BeadArray Reader to measure the
ﬂuorescence intensities. Data from the array images were analyzed
using Illumina's GenomeStudio Gene Expression Module.
RNA from formalin-ﬁxed parafﬁn-embedded samples was extracted
using the MasterPure Complete DNA and RNA Puriﬁcation Kit (Epicen-
ter Biotechnologies, Madison, WI, USA). The microarray experiments
were performed on Illumina's WG-DASL platform as previously de-
scribed (Singh et al., 2015; Guo et al., 2016). In brief, the RNA samples
(0.25–1.0 μg) were reverse transcribed to biotinylated cDNAs using
the Master Mix cDNA Synthesis kit. The biotinylated cDNAs were
annealed to assay speciﬁc chimeric-oligos containing universal PCR
priming sites and a gene-speciﬁc sequence. The cDNA-oligo complexes
were captured by strepavidin-conjugated paramagnetic particles. The
captured cDNA templates were ampliﬁed with a pair of ﬂuorophore la-
beled universal PCR primers. The labeled single stranded PCR products
were hybridized to Illumina HumanHT-12 DASL Expression BeadChips
containing the gene-speciﬁc complimentary sequences. After hybridiza-
tion, ﬂuorescence intensities were measured at each bead location on
the array using Illumina BeadArray Reader. Array data export,processing and analyses were performed with Illumina BeadStudio
v3.1.3 (Gene Expression Module V3.3.8).
2.2.2. Tissue Microarrays and Immunohistochemistry
Parallel tissue microarrays comprising 76 cases obtained from MD
Anderson formalin-ﬁxed and parafﬁn-embedded cohort were designed
and prepared as previously described (Wang et al., 2002; Kim et al.,
2005). Expression of selected genes was measured by immunohisto-
chemical staining. Brieﬂy, tissuemicroarrayswere created using a tissue
arrayer (Beecher Instruments, Silver Spring, MD). Based on gene ex-
pression proﬁles, a set of antibodies was selected for immunohisto-
chemical analyses of luminal, basal, and p53-like subtypes. The
luminal markers included mouse monoclonal antibody against human
GATA3 (HG3-31 clone, 1:100 dilution; Santa Cruz Biotechnology Inc.,
Santa Cruz, CA), KRT18 (DC10, 1:50 dilution, Dako, Carpinteria, CA),
KRT20 (Ks20.8 clone, 1:400 dilution, Dako), uroplakin 2 (BC21 clone,
1:100 dilution; Biocare Medical, Concord, CA), cyclin D1 (SP4 clone,
1:40 dilution, Lab Vision Corp, Fremont, CA), and ERBB2/HER2 (e2-
4001 clone. 1:300 dilution, Lab Vision Corp, Fremont, CA); KRT5/6
(D5/16B4 clone, 1:50 dilution, Dako), KRT14 (LL002 clone, 1:50 dilu-
tion; BioGenex, Fremont, CA), and p63 (4A4 clone, 1:1000 dilution,
BioCare Medical, Concord, CA) antibodies were selected as candidate
basal markers and p16 (E6H4 clone, 1:3 dilution, VentanaMedical, Tuc-
son, AZ), BCL2 (100 clone, 1:200 dilution, Leica Microsystems, Newcas-
tle Upon Tyne, UK), smooth muscle actin (1A4 clone, 1:80,000 dilution,
Sigma-Aldrich, St. Louis, MO), myosin (MY32 clone, 1:1000 dilution,
Invitrogen, Waltham, MA), calponin (CALP clone, 1:2000 dilution,
Dako) and desmin (D33 clone, 1:200 dilution, Dako) as p53-like
markers. Immunohistochemical stains were performed using the
Bond-Max Autostainer (Leica Biosystems, Buffalo Grove, IL). The
bound primary antibodies were detected with the visualization reagent
linked to a dextran polymer backbone with DAB (3, 3-diaminobenzi-
dine) as a chromogen solution. Then, the slides were counterstained
with Mayer's hematoxylin. The immunohistochemical results were ini-
tially inspected visually under the microscope and semi-quantitatively
assessed and scored by two pathologists as follows: 0, negative; 1+,
weak; 2+, moderate; and 3+, strong. Then, for selected markers we
performed a quantitative image analysis using an automated digital
image analyzer, GenoMx (BioGenex). The proportions of tumor cell nu-
clei positive forGATA3 staining and theproportion of positive tumor tis-
sue for all remaining markers were measured.
2.3. Statistical Analysis
Data processing and statistical analyses were performed using R
package available from the Bioconductor website (http://www.
Bioconductor.org). The gene signal values from the array data for the
MD Anderson cohorts of fresh and formalin-ﬁxed parafﬁn-embedded
samples were transformed to logarithmic scale and normalized by the
sample-wise medians. The data were subjected to hierarchical cluster-
ing analyses using Euclidean distance and average linkage algorithm
as distance metric. Samples were classiﬁed into luminal and basal mo-
lecular subtypes as previously described (Choi et al., 2014a). In addition,
subsets of tumors characterized by the upregulation of p53 target genes
were identiﬁed (Choi et al., 2014a). Similar clustering analyses were
performed for the genome-wide expression data on the Lund and The
Cancer Genome Atlas cohorts and tumors were assigned to speciﬁc
subtypes by applying the set of luminal, basal and p53-like markers de-
scribed previously (Choi et al., 2014a). In addition, gene set enrichment
analyses (GSEA) were performed to evaluate the signiﬁcance of gene
expression signature enrichment inmolecular subsets of bladder cancer
(Subramanian et al., 2005). Mutational data were downloaded from the
Cancer Genome Atlas portal (https://tcga-data.nci.nih.gov/tcga/).
MutSigCV (version 1.4; https://www.broadinstitute.org/cancer/cga/
mutsig) and used to identify genes that were mutated more often
than expected by chance given the background mutation processes
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cutoff of false discovery rate b 0.05. The statistical signiﬁcance of associ-
ation between themutations and themolecular subtypeswere assessed
by Fisher's exact test. RPPA data of 126 samples comprising of 190 pro-
teins from the TCGA cohort were processed using R package in
Bioconductor (http://www.bioconductor.org) and ANOVA analysis
was used to identify proteins with the expression levels associated
with molecular subtypes of bladder cancer. By performing pair-wise t-
tests, subsets of proteins up-regulated in speciﬁc molecular subtypes
were identiﬁed. Linear discrimination and support vectormachine anal-
yses were used to determine the best combination of immunohisto-
chemical biomarkers to predict molecular subtypes. Leave-one-out
cross-validation was employed to evaluate the performance of the clas-
siﬁers. Survival outcomes of different molecular subtypes were ana-
lyzed using log-rank test and Kaplan-Meier curves. The associations of
molecular types of bladder cancer with survival were also analyzed in
a multivariate fashion with histologic grade, stage, age, and gender as
covariates.
3. Results
To visualize the intrinsic luminal and basal molecular subtypes of
bladder cancer, we performed supervised hierarchical clustering of
basal and luminal biomarkers using whole transcriptome expression
data from four independent cohorts of bladder cancer samples (Fig. 1).
Three of these cohorts were composed of fresh frozen tumor samples:
the MD Anderson cohort (n = 132); the TCGA cohort (n = 408); and
the Lund cohort (n = 308). The fourth MD Anderson cohort contained
retrospectively collected formalin-ﬁxed and parafﬁn-embedded blad-
der tumor samples (n = 89).
First, we analyzed the MD Anderson cohort which included 34 su-
perﬁcial (Ta-Tis) and 98 invasive (T1 and higher) bladder cancers fur-
ther classiﬁed into low- and high-grade histologic categories. We
identiﬁed two major groups of samples. The ﬁrst group was character-
ized by the strong expression of luminal markers such as KRT20,
GATA3, FOXA1, XBP1 and CD24 among others signifying intermediate
and terminal urothelial differentiation referred to as luminal type (Fig.
2A). This group consisted of 92 (70%) of the samples and included 24
low-grade tumors and 68 high-grade invasive tumors. Another subset
(n = 35; 26%) of the tumors displayed strong expression of highMDA cohort (n=132)
Luminal/basal expression profile
TCGA cohort (n=408)
Luminal/basal expression profile
Mutational and RPPA analyses
Lung cohort (n=308)
Luminal/basal expression profile
MDA FFPE cohort (n=89)
Luminal/basal expression profile
Luminal/basal IHC markers 
Fig. 1. Organizational ﬂow-chart of meta-analysis in four cohorts of bladder cancer
samples.molecular weight keratins (KRT5, KRT6 and KRT14) and co-expressed
CDH3 and CD44 characteristic of the basal urothelial cell layer and
were referred to as basal-type (Fig. 2B). The luminal tumors were char-
acterized by the upregulation of PPARγ target genes while the basal tu-
mors were characterized by the upregulation of p63 target genes, all of
which were conﬁrmed by GSEA analyses (Fig. S1A–D). In addition, a
subset of tumors in both luminal and basal groups showed the upregu-
lation of p53 target genes that was referred to as p53-like subtype (Fig.
2C). This subtype consisted of 40 tumors and 21 of them were luminal
and 19 were basal. A small fraction of tumors (n = 5; 4%) did not ex-
press either luminal or basal markers and were referred to as “double-
negative” (Fig. 2A, B). Since subsets of tumors with such characteristics
were identiﬁed in human breast and bladder cancer before and showed
low expression signature of claudin related genes,we tested the expres-
sion levels of claudin target genes in a double-negative subset of bladder
tumors (Choi et al., 2014a;McConkey et al., 2015). This showed that our
double-negative tumors were indeed characterized by low expression
signature of claudin related genes (Fig. 2D).
Next we evaluated the cohort of 308 cases from Lund for the pres-
ence of intrinsic molecular subtypes of bladder cancer. Like the MD An-
derson cohort, this cohort included not only invasive bladder tumors,
but also contained a signiﬁcant proportion of superﬁcial non-invasive
lesions. Similar to the two other cohorts, two groups of bladder cancer
samples, referred to as luminal (n= 251) and basal (n= 41), with up-
regulation of PPARγ and p63 signature genes, respectively, were identi-
ﬁed (Fig. S2A–C and Fig. S3A–D). Again, a subset of tumors in both
luminal (n = 76) and basal (n = 12) subtypes showed overexpression
of p53 pathway signature genes (Fig. SC). Additionally, a small subset of
double-negative tumors (n= 16; 5%) with claudin-low expression sig-
nature was identiﬁed (Fig. S2A, B and D).
We then validated the presence of the same intrinsic molecular sub-
types on 408 cases of high-grade invasive bladder cancers from the pub-
licly available TCGA cohort. By applying our classiﬁcation algorithm,
similar to our MD Anderson cohort, tumors could be segregated into
two major groups. One group of tumors (n = 212; 52%) exhibited the
luminal expression signature while the other group (n = 189; 44%)
expressed basal markers (Fig. S4A, B). Moreover, a subset of tumors
(n = 160) exhibited p53 target expression signature and of these 79
were luminal and 81 were basal (Fig. 4C). Similarly, luminal tumors
were characterized by the enrichment of PPARγ target genes while
basal tumors showed the expression signature of p63 target genes
(Fig. S5A–D). In addition, a small subset of double-negative tumors
(n= 17; 4%) which did not show expression signatures of either lumi-
nal or basal cancers and was characterized by the downregulation of
claudin target genes, was also identiﬁed (Fig. S4A, B, and D).
The TCGA cohort provided an opportunity to analyze themutational
and protein expression patterns of the molecular subtypes of bladder
cancer (Fig. 3A–C). First we analyzed the mutations in the two intrinsic
luminal and basal subtypes. Since there were only 17 cases classiﬁed as
double negative, theirmutationswere recorded in ﬁgures and tables but
the quantitativemutational analyses of these caseswere not performed.
Whole genome sequencing of 408 tumors identiﬁed 99,983 non-synon-
ymous somatic mutations including 97,685 point mutations and 2298
insertions or deletions, yielding themean andmedian somaticmutation
load per case of 244 and 170, respectively. A small portion of cases
showed a high mutational rate with 1.5% of cases having N1000 non-
synonymous mutations and 8.8% of cases having N500 non-synony-
mous mutations. Among the luminal cancers, the mean and median
numbers ofmutations per casewere 258 and 177 respectively. A similar
mutational rate was found in basal cancers with the mean and the me-
dian number of mutations per case being 225 and 160 respectively.
MutSigCV (v1.4) identiﬁed 31 genes which showed statistically signiﬁ-
cant levels of recurrent somatic mutations. The ﬁve most frequently
mutated genes included TP53 (47%), ARID1A (25%), KDM6A (22%),
PIK3CA (22%), and RB1 (17%). The genes identiﬁed as statistically signif-
icantly mutated included, in general, multiple genes involved in cell
p53-like
Luminal
Lum
inal
p53-like
Basal
Claudin
Basal
D
ou
bl
e 
Ne
g.
Grade
Low GradeGrade: High Grade
Superficial InvasiveInvasiveness:
Invasiveness
CYP2J2
ERBB2
ERBB3
FGFR3
FOXA1
GATA3
GPX2
KRT18
KRT19
KRT20
KRT7
KRT8
PPARG
XBP1
ACTG2
CNN1
MYH11
MFAP4
PGM5
FLNC
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PCP4
CD44
CDH3
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D
Fig. 2.Whole-genomemessenger RNA proﬁling of fresh frozen bladder tumor samples in the MD Anderson cohort (n = 132). Unsupervised hierarchical clustering was performed with
luminal, p53-like, basal, and claudin markers. A. Expression pattern of signature luminal markers. B. Expression pattern of signature basal markers. C. Expression pattern of signature p53
target genes. D. Expression pattern of signature claudin target genes.
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as reported previously (Cancer Genome Atlas Research N, 2014). The
overall mutational landscape of luminal and basal bladder cancers was
similar but several geneswere distinctively enriched for theirmutations
in speciﬁc molecular subtypes. The mutations of four genes (FGFR3,
ELF3, CDKN1A, and TSC1) were enriched in luminal tumors (Supple-
mental Tables S1–4) while the basal tumors were enriched for the mu-
tations of TP53, RB1, andNFE2L2 genes (Supplemental Tables S5–7). For
some of these genes, their mutational enrichments, in speciﬁc, molecu-
lar subtypes, were particularly evident when themutational patterns of
the functional domains of their encoded proteinwere analyzed (Fig. 3D,
Figs. S6, and S7). For FGFR3, themutations clustered in the extracellular
receptor domain and were enriched in luminal subtype. A particularly
strong enrichment was observed in the ETS encoding domain of theELF3 gene where 20 of 22 mutations clustered in the luminal subtype.
On the other hand, 15 of 17 deleterious mutations of the NFE2L2 gene
involved the Neh2 domain and affected the basal subtype.
The RPPA expression levels of 190 proteins were available for 127
TCGA bladder tumor samples. By using the molecular subtype identiﬁ-
cations based on cDNA expression levels from the same cohort, we per-
formed analyses of variance (ANOVA) and identiﬁed 46 proteins that
were signiﬁcantly (p b 0.05) differentially expressed among the molec-
ular subtypes. By performing t-tests we found that 34 of these proteins
were signiﬁcantly up-regulated in one of the molecular subtypes of
bladder cancer (Fig. 4A–C). This approach showed that 17 of the pro-
teins were up-regulated in the luminal subtypes and included GATA3,
E-Cadherin, HER2/3, Rab-25, and Src among others (Fig. 4A). There
were eight proteins up-regulated in the basal subtype, which included
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110 V. Dadhania et al. / EBioMedicine 12 (2016) 105–117Anexin-1, CD49, Cyclin B1, and EGFR (Fig. 4B). The nine proteins identi-
ﬁed as overexpressed in the p53-like tumors included Caveolin-1, Colla-
gen VI, Fibronectin, and PKC alpha among others (Fig. 4C).Because the analyses of the three independent bladder cancer co-
horts of frozen fresh tumor samples conﬁrmed the presence of the in-
trinsic luminal and basal types of the disease, we proceeded to analyze
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111V. Dadhania et al. / EBioMedicine 12 (2016) 105–117the formalin-ﬁxed and parafﬁn-embedded cohort aswell as the parallel
tissue microarray. The goal of this analysis was to address the question
of whether the genome proﬁlingwith the identiﬁcation of intrinsic mo-
lecular subtypes of bladder cancer can be successfully performed on for-
malin-ﬁxed and parafﬁn-embedded tissue, which is routinely used for
clinical management. In addition, we wanted to identify a limited set
of biomarkers that could be used to subclassify bladder cancer into sub-
types by simple immunohistochemical tests that can be applied to the
management of bladder cancer patients in primary care centers around
the world. Similar to the three fresh frozen bladder cancer tissue co-
horts, the formalin-ﬁxed and parafﬁn-embedded samples could be di-
vided into luminal (n = 46; 52%) and basal (n = 29; 32%) groups
(Fig. 5A, B). In addition, a subset of tumors with the wild-type p53
gene expression signature was identiﬁed (n = 39; 44%); 28 of which
were luminal and 11 were basal (Fig. 5C). Analogous to the fresh frozen
tumor sample cohorts, the luminal parafﬁn-embedded tumor samples
exhibited PPARγ pathway activation and basal tumors showed the up-
regulation of the p63 transcription factor pathway genes (Fig. S8A–D).
As in the other cohorts, a small group of double-negative tumors
(n = 14, 16%) which did not express either luminal or basal markers
with claudin-low expression signaturewas identiﬁed (Fig. 5A, B, andD).
In order to identify immunohistochemical markers to classify blad-
der cancers into basic intrinsic molecular categories we used genomic
expression proﬁling to select a set of markers that are routinely used
in the pathologic diagnostic workup of human tumor samples. These in-
cluded the GATA3 transcription factor, KRT18, KRT20, uroplakin 2, cy-
clin D1, and ERBB2/HER2 as candidate luminal markers and KRT5/6,
KRT14, and p63 as candidate markers of basal tumors. In addition, we
selected p16, BCL2, smooth muscle actin, myosin, calponin, and desmin
for p53-like subtype. The initial microscopic inspection of tissue micro-
array stained for these markers showed that several of the markers
(smooth muscle actin, myosin, calponin, and desmin) that wereselected for the p53-like subset of tumors stained only the stromal tis-
sue interveningwith the nests of cancer cells, and noneof thesemarkers
were convincingly positively stained in tumor cells. The stromal compo-
nents comprising either smooth muscle inﬁltrated by tumor cells or the
so called stromal induction composed of ﬂorid proliferations of
myoﬁbroblastic cells intermixedwith the nests of tumor cells were pos-
itive for the mesenchymal markers that, in fact, represented the signa-
ture of stromal smooth muscle or myoﬁbroblastic differentiation (Fig.
6). In addition, staining for another p53-like marker, BCL2, an anti-apo-
ptotic protein, showed that inﬂammatory cells inﬁltrating tumors were
positivewhile the tumor cells were negative. Therefore, themicroscopic
analysis of the immunohistochemical stains of the so called p53-like tu-
mors provided evidence that most of their markers were not distinc-
tively positive in tumor cells and the p53-like signature proﬁle
resulted from stromal contamination. The remaining p-53 marker
(p16) did not show signiﬁcant difference in expression between p53-
like and non-p53-like tumors. In addition, the ERBB2/HER2 stains
were only positive in 3 cases of luminal p53-like tumors. Therefore it
was not considered to represent an effective differentiation marker
and was not further analyzed. The immunohistochemical expression
levels of the remaining luminal and basal markers were semi-quantita-
tively scored and their results are summarized in Fig. 7A. The expression
patterns of some of thesemarkers (p63, cyclin D1, KRT18) showed clear
overlap in the luminal and basal subtypes, but ﬁve of them (KRT5/6 and
KRT14 for basal tumors and GATA3, KRT20, and uroplakin 2 for luminal
tumors) showed promising differential expression patterns and they
were selected for further analyses (Fig. 7B). Firstwe addressed the ques-
tion whether the immunohistochemical expression levels in tissue mi-
croarrays could be correlated with their cDNA expression levels used
as the original classiﬁers. These analyseswere performed on the parallel
sample sets from the formalin-ﬁxed and parafﬁn-embeddedMDAnder-
son cohort (Fig. S9A–E). For GATA3 in addition to comparing its cDNA
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112 V. Dadhania et al. / EBioMedicine 12 (2016) 105–117and protein expression levels in the MD Anderson cohort, we used the
RNASeq and RPPA expression levels from the TCGA cohort (Fig. S9F).
All of the proteins analyzed showed statistically signiﬁcant correlation
between their immunohistochemical expression, quantitated by
image analysis, and their cDNA expression levels.
When the results from image analyses were compared with mRNA-
based tumor subtype assignments, it became evident that the luminal
tumors were clearly enriched for the immunohistochemically detect-
able protein expression levels of luminal markers while the basal tu-
mors showed clear enrichment for expressions of basal markers (Fig.
8A). Although, in general, tumors classiﬁed as luminal based on genome
expression proﬁling were positive for luminal markers (GATA3, KRT20,
and uroplakin) and basal tumors were positive for basal makers (KRT5/
6 and KRT14), there was signiﬁcant overlap between these two sets of
markers, particularly evident in the luminal category. When tumors
were clustered according to quantitative immunohistochemical expres-
sion levels, they were classiﬁed into two distinct groups designated as
clusters A and B corresponding to luminal and basal subtypes. We per-
formed this clustering using different cut-off expression levels corre-
sponding to 10, 20, 30, and 40% of tumor tissue positivity for KRT5/6,
KRT14, KRT20, and uroplakin. The cut-off expression levels of 10, 20,
30, and 40% of tumor nuclei positivity were used for GATA3. Regardless
of the cut-off positivity level, the tumors were segregated into two
major groups referred to as clusters A and B corresponding to luminal
and basal categories. The best segregation of speciﬁc molecular
subtypes into their respective clusters was accomplished with 20%
tumor tissue positivity and 20% tumor nuclei positivity cut-off levels
(Fig. 8B). At these cut-off levels, all but one of the tumors classiﬁed asluminal by genome expression proﬁling were in cluster A. Cluster B
contained almost exclusively basal tumors. Unfortunately, due to the
overlapping expression between immunohistochemical luminal and
basal markers, several basal tumors (8; 28%) co-clustered with luminal
tumors in cluster A. In addition, all double-negative tumors were classi-
ﬁed by immunohistochemical expression levels as luminal as a part of
cluster A. In order to ﬁnd the best immunohistochemical classiﬁer of
molecular subtypes of bladder cancer, we performed box-type analyses
of the marker expression levels which showed that KRT5/6, KRT14 and
GATA3may be themost efﬁcient markers withminimal overlap to clas-
sify the tumors into luminal and basal subtypes (Fig. 8C). We veriﬁed
this by performing logistic regression and support vector machine anal-
yses inwhichwe analyzedmodels of all combinations ofmarker expres-
sion levels and showed that KRT5/6 and GATA3 represent the best pair
of markers classifying the tumor into molecular categories with a 91%
accuracy (Fig. 8D). The secondmost effective pair of markers was kera-
tin 14 and GATA3, which classiﬁed the tumors into luminal and basal
subtypes with 89% accuracy (Fig. S10). In these analyses the support
vector machine performed in a similar fashion to logistic linear regres-
sion and did not improve the accuracy of the classiﬁer. In both of the an-
alytical models the majority of double-negative tumors were in the
luminal category.
Since the intrinsic molecular subtypes of bladder cancer were re-
ported previously to have differences in clinical behavior with basal tu-
mors being more aggressive when compared to luminal tumors, we
performed survival analyses on all four cohorts (Fig. 9A–D, Table 1). Dis-
ease speciﬁc survival analyses were performed on both fresh frozen and
formalin-ﬁxed parafﬁn-embedded MD Anderson cohorts while for the
twopublically available cohorts, i.e., Lund and TCGA, only overall surviv-
al analyses could be performed. In addition, two cohorts (fresh frozen
tissue MD Anderson and the Lund cohorts) included superﬁcial non-in-
vasive tumors and these groups were separately analyzed and com-
pared to invasive tumors. Initially the invasive tumors were separated
into three sub-groups based on their expression proﬁles and classiﬁed
as luminal, basal and double-negative. Since the number of cases with
follow-up for the double-negative group was insufﬁcient in some of
the cohorts, the survival analyses for this group was not performed on
the fresh frozen tissue MD Anderson and Lund cohorts. In all four co-
horts, the invasive basal tumors were more aggressive as compared to
invasive luminal tumors and were associated with a signiﬁcantly
shorter survival. The difference was particularly striking when the dis-
ease speciﬁc-survival was analyzed in the two MD Anderson cohorts.
The double-negative tumors were more aggressive in the TCGA cohort
when compared to basal tumors in the TCGA cohort but the Kaplan-
Meier curve of the double-negative tumors in the MD Anderson cohort
of archival parafﬁn-embedded samples overlapped with that of basal
tumors and the differences in survival between double-negative and
basal tumors were statistically insigniﬁcant.
Next, we included in the analyses the p53-like tumors and separated
the luminal and basal tumors into two subgroups deﬁned as luminal or
basal non-p53-like and luminal or basal with p53-like signature. In
these analyses we addressed the question whether the p53-like tumors
have distinct clinical behavior. These analyses did not disclose signiﬁ-
cant differences in clinical behavior of p53-like tumors across the co-
horts. The survival curves of the tumors with p53-like signatures
either overlapped with the survival curves of the tumors exhibiting lu-
minal or basal phenotypes or were between them. The p53-like basal
tumors displayed signiﬁcantly more aggressive behavior in the forma-
lin-ﬁxed and parafﬁn-embedded MD Anderson cohort only.
Finally, we addressed the issue of whether the molecular subtypes
are associated with clinical outcome when analyzed together with
other parameters such as histologic grade and stage of the tumor
stage as well as the patient's age and gender in a multivariate analysis.
In both MD Anderson cohorts as well as in the TCGA cohort the molec-
ular subtypes were signiﬁcantly associated with outcomes in themulti-
variate analysis togetherwith tumor grade, stage, aswell as thepatient's
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subtypes, the p53-like tumors are showing the expression of SMA or desmin in the stromal component of the tumor while the tumor cells do not express these markers. Scale bars
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113V. Dadhania et al. / EBioMedicine 12 (2016) 105–117age and gender. In particular, it was evident that luminal subtype was
associated with more favorable outcome when compared to basal sub-
type. These associations were not, however, evident in the Lund cohort
in which the molecular subtypes were not independent predictors of
the outcome in the multivariate analysis.4. Discussion
Our meta-analysis of the genome expression proﬁles on several
large cohorts, comprising a total of 937 bladder cancer tumor samples
with annotated clinical data, showed that bladder cancers can be consis-
tently and reliably classiﬁed into two intrinsic molecular types, luminal
and basal. These classiﬁcations can be successfully performed, not only
on fresh frozen tumors but also on formalin-ﬁxed and parafﬁn-embed-
ded archival samples. Moreover, parallel analyses of genomic expres-
sion proﬁles and immunohistochemical expression patterns in tissue
microarrays identiﬁed a limited number of biomarkers that can be
used to classify bladder cancer into its intrinsicmolecular types. The im-
munohistochemical expression levels of just two signatures markers,
one luminal and the other basal, speciﬁcally GATA3 and KRT5/6 respec-
tively, are sufﬁcient to classify bladder cancers into luminal and basal
categories with over 90% accuracy but the performance of this classiﬁer
should be further validated on larger independent cohorts. Survival
analyses conﬁrmed that invasive luminal and basal bladder cancers
had distinctively different clinical behaviors. The differences were par-
ticularly evident when disease speciﬁc survival was analyzed. The
basal tumors were consistently more aggressive when compared to lu-
minal tumors and were associated with signiﬁcantly shorter survival
than luminal tumors.A small fraction (4–16%) of double-negative cases characterized by
the low level of expression of either luminal or basal markers was iden-
tiﬁed in all cohorts. These cases appear similar to a previously identiﬁed
subcategory of bladder and breast cancers with down regulated claudin
target genes (Damrauer et al., 2014; Prat et al., 2010). The previously
identiﬁed category of so called p53-like tumors was identiﬁed as a sub-
group of both luminal and basal tumors. In addition, a fraction of dou-
ble-negative tumors were also characterized by the expression
signature of p53 target genes. The microscopic inspection of the immu-
nohistochemical stains of tumors classiﬁed by expression proﬁling as
p53-like, disclosed that the markers used for their identiﬁcation were
expressed in the stromal componentwhile the tumor cells were, in gen-
eral, negative. This indicated that the so called p53 phenotype resulted
from the contamination of the tumor tissue with stromal components.
The RPPA data from the TCGA cohort provides additional clues by show-
ing that the proteins overexpressed in the p53-like subtypes in general
belong to the category of the so-called mesenchymal markers. This was
particularly evident when the tumor inﬁltrated the smooth muscle of
the bladder or in the areas of the so called stromal induction which
contained ﬂorid proliferations of myoﬁbroblastic cells. Such samples
showed strong stromal overexpression of smooth muscle and
myoﬁbroblastic markers in the stromal tissue surrounding the nests of
tumor cells. This data strongly suggests that stromal contaminations
might have contributed to the identiﬁcation of the so-called p53-like
phenotype and indicate that further analyses should be performed
with puriﬁed tumor tissue such as laser microdissection. Previous stud-
ies demonstrated that membership in the p53-like subtype was unsta-
ble and could be enhanced by exposure to neoadjuvant chemotherapy
(Choi et al., 2014a). Therefore, the p53-like subtype does not appear
to be an “intrinsic” subtype of bladder cancer. Nevertheless, these
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114 V. Dadhania et al. / EBioMedicine 12 (2016) 105–117inﬁltrated tumors tended to be chemoresistant (Choi et al., 2014a), and
data froma recently completed Phase II clinical trial of the blocking anti-
PDL1 antibody atezolizumab suggest that patients with inﬁltrated
(TCGA cluster II) tumors obtained the most clinical beneﬁt from the
drug (Rosenberg et al., 2016). Therefore, it may be useful to distinguishthese inﬁltrated basal and luminal tumors from the others when
selecting patients for neoadjuvant or adjuvant therapy.
The overall mutational pattern of luminal and basal subtypes was
similar but there were several genes that have their mutations enriched
in speciﬁc molecular subtypes. The mutations of FGFR3, ELF3, CDKN1A,
and TSC1 were enriched in luminal subtypes. The mutations of TP53,
RB1, and NFE2L2 were enriched in basal tumors. However, the frequen-
cy of the involvement of these genes was too low and there was also an
overlap in their involvement inmolecular subtypes precluding their use
as effective molecular classiﬁers. The protein expression pattern of mo-
lecular subtypes revealed by RPPA provided a roster of proteins distinc-
tively overexpressed in luminal and basal subtypes. They included E-
Cadherin, HER2/3, Rab-25, and Src as markers of luminal tumors and
CD49, Cyclin B1 and EGFR as markers of basal tumors. These proteins
in addition to contributing to a list of potential markers of molecular
subtypes may represent attractive therapeutic targets.
Molecular subtypes of bladder cancer resemble those originally
identiﬁed in human breast carcinomas that can also be divided into lu-
minal and basal subtypes using a similar set of markers (Perou et al.,
2000). Several groups independently classiﬁed bladder cancer into dis-
tinct subtypes by using genomic expression proﬁling (Cancer Genome
Atlas Research N, 2014; Damrauer et al., 2014; Choi et al., 2014a;
Lindgren et al., 2010; Sjodahl et al., 2012). One of these groups divided
bladder cancers into two subtypes, (Damrauer et al., 2014) another clas-
siﬁed them into three subtypes, (Choi et al., 2014a) and the third con-
cluded that there were four distinct molecular categories of bladder
cancer, (Cancer Genome Atlas Research N, 2014) while the fourth pro-
posed the classiﬁcation scheme based on ﬁve subcategories (Sjodahl
et al., 2012). Although these groups used different names for their re-
spective categories they used overlapping sets of markers that were
originally used to subclassify breast cancers (Perou et al., 2000). The
subtypes of bladder cancer identiﬁed by these groups show overlapping
expression signatures with at least three of the previously identiﬁed
molecular subtypes referred to as squamous, genomically unstable,
and inﬁltrated (Sjodahl et al., 2012). From these investigations it is evi-
dent that bladder cancer is not only clinically and pathologically, but
also molecularly, a heterogeneous disease. However, there is a general
consensus that the top-level separation occurs at the basal and luminal
differentiation checkpoint proposed by the group at the University of
North Carolina (Damrauer et al., 2014). Although the well-known
study of bladder cancer molecular subtypes performed by the group at
the University of Lund, Sweden identiﬁed ﬁve distinct molecular sub-
types, termed urobasal A, genomically unstable, inﬁltrated, urobasal B
and squamous cell carcinoma-like, more recently the same group
reconciled their subtypes with the basal and luminal phenotypes
identiﬁed by the University of North Carolina (Aine et al., 2015). Spe-
ciﬁcally they showed that the urobasal A and genomically unstable
tumors were contained within the luminal subtype cluster whereas
the inﬁltrated, urobasal B, and squamous cell carcinoma-like tumors
were contained within the basal subtype cluster (Aine et al., 2015).
Similarly, even though the Cancer Genome Atlas group concluded
that bladder cancers could be subdivided into four clusters, it recog-
nized that clusters I and II were enriched with luminal markers and
their gene expression signatures whereas clusters III and IV
contained basal or mesenchymal markers characteristic of the basal
subtype identiﬁed by the University of North Carolina (Cancer
Genome Atlas Research N, 2014).
In summary, our studies conﬁrmed the existence of two distinctmo-
lecular subtypes of bladder cancer referred to as luminal and basal. The
luminal cancers appear to evolve through the papillary trackwhile basal
forms were nonpapillary. The superﬁcial papillary tumors were exclu-
sively luminal while the invasive bladder cancers can be almost equally
divided into luminal and basal types. In this scenario, those invasive tu-
mors that show luminal expression signatures most likely evolve from
the preexisting papillary disease and likely represent a progression of
superﬁcial papillary tumors.
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Fig. 8. Quantitative image-based immunohistochemical analysis of selected luminal and basal markers in formalin-ﬁxed and parafﬁn-embedded tumor samples (n = 76) in the MD
Anderson cohort. A. Expression levels of selected luminal and basal markers in tissue microarray analyzed by quantitative image analysis. The cases were classiﬁed and clustered on
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expression levels of signature luminal and basal markers revealed by immunohistochemistry and analyzed by quantitative image analysis. C. Mean expression levels of signature
luminal and basal markers revealed by immunohistochemistry and quantitated by image analysis. D. Logistic regression (LRA) and support vector machine (SVM) analyses using the
immunohistochemical levels of two signature markers: luminal (GATA3) and basal (KRT5/6).
115V. Dadhania et al. / EBioMedicine 12 (2016) 105–117Our unpublished genomic whole-organ studies suggest that luminal
and basal tumors develop from preexisting diffuse mucosal ﬁeld effects
which retain the expression signature of their respective luminal and
basal tumors. Further support for early dichotomy of bladder carcino-
genesis is provided by recent animal lineage tracing studies in the BBN
mouse model (Van Batavia et al., 2014; Shin et al., 2014a; Shin et al.,
2014b; Czerniak et al., 2016). These studies implicate that basal and lu-
minal forms of bladder cancers are derived from distinct progenitor
cells. Basal cancers originate from KRT5 and Sonic hedge-hog-positive
basal uroprogenitor cells while papillary luminal tumors are derived
from the intermediate cells (Shin et al., 2014b). In addition, the molec-
ular subtypes of bladder cancer show distinct mutation signature and
involvement of transcription factors which may represent therapeutic
targets (Cancer Genome Atlas Research N, 2014). Our meta-analysis ofbladder cancer subtypes has important implication for management of
patients with bladder cancer by providing tools for prognostication
and selection for speciﬁc therapies.
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Fig. 9. Survival analyses in four independent cohorts. A. Fresh frozen tumor samples in theMD Anderson cohort (n= 132). B. Fresh frozen tumor samples in the Lund cohort (n= 308). C.
Fresh frozen tumor samples in the TCGA cohort (n = 408). D. Formalin-ﬁxed and parafﬁn-embedded samples in the MD Anderson cohort (n = 89). Left panels in each cohort show the
Kaplan-Meier plots of luminal, basal, and double-negative subtypes. Right panels in each cohort show the Kaplan-Meier plots of luminal and basal cancers divided into non-p53-like and
p53-like subtypes. The superﬁcial non-invasive tumors in the fresh frozen tumor samples of the MD Anderson and the Lund cohorts were analyzed as a separate group. The survival
analyses for the double-negative group were not performed in the fresh frozen tumor samples of the MD Anderson and the Lund cohorts because of the insufﬁcient number of cases
for follow-up data.
116 V. Dadhania et al. / EBioMedicine 12 (2016) 105–117
117V. Dadhania et al. / EBioMedicine 12 (2016) 105–117responsible for design and statistical analysis of genomic expression
proﬁles. VD and LZ performed the mutational analysis of the TCGA co-
hort. ASR and CD provided and analyzed clinical data.
Declaration of Interest
We declare no competing interest.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.08.036.
Acknowledgements
This project was supported by National Cancer Institute grants R01
CA151489 and P50 CA91846 (Project 1 and Core C) to B.C. V.D. is sup-
ported by T32 CA163185 grants. The content is solely the responsibility
of the authors and does not necessarily represent the views of the Na-
tional Cancer Institute or the National Institutes of Health. The study
funders had no role in the design of the study, the collection, analysis,
or interpretation of the data, the writing of the manuscript, or the deci-
sion to submit themanuscript for publication. The authors thank Virgin-
ia Hurley and Stephanie Garza for administrative assistance as well as
Kim Anh Vu for graphical design.
References
Aine, M., Eriksson, P., Liedberg, F., Sjodahl, G., Hoglund, M., 2015. Biological determinants
of bladder cancer gene expression subtypes. Sci. Rep. 5, 10957.
Cancer Genome Atlas Research N, 2014. Comprehensive molecular characterization of
urothelial bladder carcinoma. Nature 507 (7492), 315–322.
Cheng, T., Roth, B., Choi, W., Black, P.C., Dinney, C., McConkey, D.J., 2013. Fibroblast growth
factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer
growth and metastasis: implications for therapeutic targeting. PLoS One 8 (2),
e57284.
Choi, W., Czerniak, B., Ochoa, A., et al., 2014b. Intrinsic basal and luminal subtypes of mus-
cle-invasive bladder cancer. Nat. Rev. Urol. 11 (7), 400–410.
Choi, W., Porten, S., Kim, S., et al., 2014a. Identiﬁcation of distinct basal and luminal sub-
types of muscle-invasive bladder cancer with different sensitivities to frontline che-
motherapy. Cancer Cell 25 (2), 152–165.
Czerniak, B., Dinney, C., McConkey, D., 2016. Origins of bladder cancer. Annu. Rev. Pathol.
11, 149–174.
Damrauer, J.S., Hoadley, K.A., Chism, D.D., et al., 2014. Intrinsic subtypes of high-grade
bladder cancer reﬂect the hallmarks of breast cancer biology. Proc. Natl. Acad. Sci.
U. S. A. 111 (8), 3110–3115.
Dyrskjot, L., Thykjaer, T., Kruhoffer, M., et al., 2003. Identifying distinct classes of bladder
carcinoma using microarrays. Nat. Genet. 33 (1), 90–96.
Groenendijk, F.H., de Jong, J., van de Putte EE, F., et al., 2016. ERBB2mutations characterize
a subgroup of muscle-invasive bladder cancers with excellent response to neoadju-
vant chemotherapy. Eur. Urol. 69 (3), 384–388.Gui, Y., Guo, G., Huang, Y., et al., 2011. Frequent mutations of chromatin remodeling genes
in transitional cell carcinoma of the bladder. Nat. Genet. 43 (9), 875–878.
Guo, C.C., Dadhania, V., Zhang, L., et al., 2016. Gene expression proﬁle of the clinically ag-
gressive micropapillary variant of bladder cancer. Eur. Urol. (March 15).
Kim, J.H., Tuziak, T., Hu, L., et al., 2005. Alterations in transcription clusters underlie devel-
opment of bladder cancer along papillary and nonpapillary pathways. Lab. Investig.
85 (4), 532–549.
Lawrence, M.S., Stojanov, P., Polak, P., et al., 2013. Mutational heterogeneity in cancer and
the search for new cancer-associated genes. Nature 499 (7457), 214–218.
Lindgren, D., Frigyesi, A., Gudjonsson, S., et al., 2010. Combined gene expression and ge-
nomic proﬁling deﬁne two intrinsic molecular subtypes of urothelial carcinoma and
gene signatures for molecular grading and outcome. Cancer Res. 70 (9), 3463–3472.
McConkey, D.J., Choi, W., Dinney, C.P., 2015. Genetic subtypes of invasive bladder cancer.
Curr. Opin. Urol. 25 (5), 449–458.
Moch, H., Humphrey, P., Ulbright, T., Reuter, V., WHO, 2016. Classiﬁcation of Tumours of
the Urinary System and Male Genital Organs. 4th ed. International Agency for Re-
search on Cancer, Lyon.
Perou, C.M., Sorlie, T., Eisen, M.B., et al., 2000. Molecular portraits of human breast tu-
mours. Nature 406 (6797), 747–752.
Prat, A., Parker, J.S., Karginova, O., et al., 2010. Phenotypic and molecular characterization
of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 12 (5), R68.
Puzio-Kuter, A.M., Castillo-Martin, M., Kinkade, C.W., et al., 2009. Inactivation of p53 and
Pten promotes invasive bladder cancer. Genes Dev. 23 (6), 675–680.
Rosenberg, J.E., Hoffman-Censits, J., Powles, T., et al., 2016. Atezolizumab in patients with
locally advanced and metastatic urothelial carcinomawho have progressed following
treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2
trial. Lancet 387 (10031), 1909–1920.
Shin, K., Lim, A., Odegaard, J.I., et al., 2014a. Cellular origin of bladder neoplasia and tissue
dynamics of its progression to invasive carcinoma. Nat. Cell Biol. 16 (5), 469–478.
Shin, K., Lim, A., Zhao, C., et al., 2014b. Hedgehog signaling restrains bladder cancer pro-
gression by eliciting stromal production of urothelial differentiation factors. Cancer
Cell 26 (4), 521–533.
Singh, R.R., Murugan, P., Patel, L.R., et al., 2015. Intratumoral morphologic and molecular
heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy.
Mod. Pathol. 28 (9), 1225–1235.
Sjodahl, G., Lauss, M., Lovgren, K., et al., 2012. A molecular taxonomy for urothelial carci-
noma. Clin. Cancer Res. 18 (12), 3377–3386.
Sobin, L., Gospodarowicz, M., Wittekind, C., 2009. TNM Classiﬁcation of Malignant Tu-
mours. 7th ed. Wiley-Blackwell, Hoboken.
Subramanian, A., Tamayo, P., Mootha, V.K., et al., 2005. Gene set enrichment analysis: a
knowledge-based approach for interpreting genome-wide expression proﬁles. Proc.
Natl. Acad. Sci. U. S. A. 102 (43), 15545–15550.
Takata, R., Katagiri, T., Kanehira, M., et al., 2005. Predicting response to methotrexate, vin-
blastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers
through genome-wide gene expression proﬁling. Clin. Cancer Res. 11 (7),
2625–2636.
Van Allen, E.M., Mouw, K.W., Kim, P., et al., 2014. Somatic ERCC2mutations correlate with
cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 4 (10),
1140–1153.
Van Batavia, J., Yamany, T., Molotkov, A., et al., 2014. Bladder cancers arise from distinct
urothelial sub-populations. Nat. Cell Biol. 16 (10), 982–991 (1–5).
Wang, H., Wang, H., Zhang,W., Fuller, G.N., 2002. Tissuemicroarrays: applications in neu-
ropathology research, diagnosis, and education. Brain Pathol. 12 (1), 95–107.
